FilingReader Intelligence

Kangmei Pharmaceutical cancels equity incentives, resolves legacy debt

July 4, 2025 at 05:10 PM UTC•By FilingReader AI

Kangmei Pharmaceutical announced the cancellation of its equity incentive plan and the resolution of a legacy debt issue.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Kangmei Pharmaceutical's announcement on the implementation of equity incentive restricted stock repurchase and cancellationJuly 4, 2025 at 08:00 AM UTC

Supplementary Source Documents

Kangmei Pharmaceutical's announcement on the passive formation of related-party transactions due to the acquisition of the company's debts by related partiesJuly 4, 2025 at 08:00 AM UTC

Kangmei Pharmaceutical

SSE:600518•Shanghai Stock Exchange

RSS feed for Kangmei Pharmaceutical

News Alerts

Get instant email alerts when Kangmei Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →